Logo Menu Black - Therapixel
logo
  • Home
  • About Us
    • Team
    • Careers
  • Product & Technology
  • Investors
  • News & Events
    • Press
  • Contact

study

October 19, 2022

Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms

The first French prospective clinical study to evaluate the…

by Neliya Tumbeva

Text

Logo Therapixel
 
Therapixel is one of the leading French software companies specialising in artificial intelligence applied to medical imaging.

LATEST BLOG NEWS

  • Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms October 19, 2022
  • Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy May 14, 2022
  • Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D May 12, 2022

RECOMMENDED POSTS

  • Therapixel announces launch of prospective study on the utility of Artificial Intelligence (AI) as part of second reading breast cancer screening mammograms
  • Therapixel releases a new version of MammoScreen® that leverages prior exams for better accuracy
  • Therapixel announces close of 15 M€ series B financing to deploy MammoScreen® 2D/3D
  • Therapixel receives FDA clearance for use of its AI-based breast cancer screening software MammoScreen® on Digital Breast Tomosynthesis
  • Therapixel will be showcasing MammoScreen™ at the virtual ECR 2021

© 2020 Therapixel | Web design by Domaine-Pack.fr

Privacy Preference Center

Privacy Preferences